Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.41 |
| ▸ | PPARA | Q07869 | 12/20 | 0.41 |
| ▸ | PPARD | Q03181 | 11/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1110220 | 0.90 | NPC1 (0.42) | PPARGPPARAPPARDMAOBTDP1 | |
| SCHEMBL1110513 | 0.89 | PPARG (0.39) | PPARGPPARAPPARDMAOBS1PR1 | |
| SCHEMBL1110207 | 0.89 | ALDH1A1 (0.45) | PPARGPPARAPPARDMAPTL3MBTL1 | |
| SCHEMBL1110145 | 0.88 | KDM4E (0.41) | S1PR1MAPTL3MBTL1 | |
| SCHEMBL1110250 | 0.86 | MMP12 (0.38) | MAOBS1PR1L3MBTL1 | |
| SCHEMBL1110146 | 0.86 | MMP2 (0.36) | PPARGPPARAPPARDS1PR1MAPT | |
| SCHEMBL1110342 | 0.84 | MMP2 (0.34) | PPARGPPARAPPARDMAPTL3MBTL1 | |
| SCHEMBL1111051 | 0.83 | EDNRB (0.36) | PPARGPPARAPPARD | |
| SCHEMBL1110305 | 0.82 | FFAR1 (0.44) | PPARGPPARAPPARDMAOBFFAR1 | |
| SCHEMBL1110198 | 0.81 | CYP3A4 (0.36) | PPARGPPARAPPARDS1PR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269761-A1 | ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| EP-2279173-A1 | NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269761-A1 | ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | SULT2A1, UGT1A1, SLC5A1 | PPARG 55/4885PPARA 294/4885PPARD 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.